ReviewCurrent pharmaceutical design2015
Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.
Review in Current pharmaceutical design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Initial antihypertensive agent effects on acute blood pressure after intracerebral haemorrhage.Stroke and vascular neurology · 2022Trial
- The bioequivalence of fixed-dose combination tablets of bisoprolol and ramipril and its drug-drug interaction potential.Clinical and translational science · 2022Trial
- Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.European journal of drug metabolism and pharmacokinetics · 2021Trial
- Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.Clinical drug investigation · 2019Trial
- Thymoquinone in Atherosclerosis: A Multi-Target Nutraceutical Modulating Inflammation, Oxidative Stress, and Lipid Metabolism.Nutrients · 2026Review
- Nirmatrelvir/Ritonavir-Induced Calcium Channel Blocker Intoxication Successfully Treated by High Dose Insulin Therapy.Acta Cardiologica Sinica · 2026Article
- Hypertension pharmacogenetics and limitations in Africa - a focus on the ACE, AGTR1 and CYP2C9 genes.Journal of human hypertension · 2026Review
- Coupled pharmacokinetic model unveils drug-drug interactions in plasma concentration.PloS one · 2026Article
- Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases.Archives of pharmacal research · 2025Review
- Cardiovascular Effects, Phytochemistry, Drug Interactions, and Safety Profile ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Fungal Biodegradation of Amlodipine and Lisinopril by Penicillium citrinum: Towards a Sustainable Approach to Pharmaceutical Wastewater Treatment.Current microbiology · 2025Article
- The Expression of GenesBiomedicines · 2024Article
- Comparison between the ECG Outcomes of Metoprolol and Bisoprolol.Cardiovascular & hematological agents in medicinal chemistry · 2024Article
- Microneedles and Their Application in Transdermal Delivery of Antihypertensive Drugs-A Review.Pharmaceutics · 2023Review
- Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review.Plants (Basel, Switzerland) · 2023Article
- Cardiovascular precision medicine - A pharmacogenomic perspective.Cambridge prisms. Precision medicine · 2023Review
- Pharmacogenomics of Hypertension in Africa: Paving the Way for a Pharmacogenetic-Based Approach for the Treatment of Hypertension in Africans.International journal of hypertension · 2023Review
- Gut microbiota and cardiac arrhythmia: a pharmacokinetic scope.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2022Review
- Integrative multiomic analyses of dorsal root ganglia in diabetic neuropathic pain using proteomics, phospho-proteomics, and metabolomics.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery and development is a high-risk enterprise that requires significant investments in capital, time and scientific expertise. The studies of xenobiotic metabolism remain as one of the main topics in the research and development of drugs, cosmetics and nutritional supplements. Antihypertensive drugs are used for the treatment of high blood pressure, which is one the most frequent symptoms of the patients that undergo cardiovascular diseases such as myocardial infraction and strokes. In current cardiovascular disease pharmacology, four drug clusters - Angiotensin Converting Enzyme Inhibitors, Beta-Blockers, Calcium Channel Blockers and Diuretics - cover the major therapeutic characteristics of the most antihypertensive drugs. The pharmacokinetic and specifically the metabolic profile of the antihypertensive agents are intensively studied because of the broad inter-individual variability on plasma concentrations and the diversity on the efficacy response especially due to the P450 dependent metabolic status they present. Several computational methods have been developed with the aim to: (i) model and better understand the human drug metabolism; and (ii) enhance the experimental investigation of the metabolism of small xenobiotic molecules. The main predictive tools these methods employ are rule-based approaches, quantitative structure metabolism/activity relationships and docking approaches. This review paper provides detailed metabolic profiles of the major clusters of antihypertensive agents, including their metabolites and their metabolizing enzymes, and it also provides specific information concerning the computational approaches that have been used to predict the metabolic profile of several antihypertensive drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.